Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafter, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D'Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green and Simon T. Barry
Urs Hancox
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabina Cosulich
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyndsey Hanson
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cath Trigwell
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Lenaghan
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Ellston
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannah Dry
2Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Crafter
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Barlaam
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Fitzek
3Discovery Sciences AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul D. Smith
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald Ogilvie
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celina D'Cruz
2Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lillian Castriotta
2Oncology iMED Gatehouse Park, Waltham, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R. Wedge
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Ward
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Powell
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mandy Lawson
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry R. Davies
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Harrington
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Foster
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Cumberbatch
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Green
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon T. Barry
1Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Simon.T.Barry@astrazeneca.com
DOI: 10.1158/1535-7163.MCT-14-0406 Published January 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Activity of AZD8186. A, AZD8186. B, inhibition of ADP-induced platelet aggregation, representative curve, and mean IC50 186 ± 36 nmol/L (SEM; n = 3). C, LPA (10 mmol/L) activation of serum-starved MDA-MB-468 and PC3 cells in the presence or absence of 250 nmol/L AZD8186 as indicated. Western blots for pAKT (Ser473), pERK, total AKT, and total ERK, with vinculin as a loading control. Representative of three similar experiments.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    AZD8186 inhibits phosphorylation of AKT and downstream pathway proteins inducing nuclear translocation of FOXO3a in vitro. A, Western blot analysis of protein phosphorylation reduction by AZD8186 in three prostate cancer cell lines. Inhibition of proliferation shown as GI50 (μmol/L ± SEM). B, Western blot analysis of protein phosphorylation reduction by AZD8186 in three breast cancer cell lines. Inhibition of proliferation shown as GI50 (μmol/L ± SEM). C, nuclear accumulation of FOXO3a in HCC70, LNCAP, and BT474 cells. Representative images show Hoescht (blue) and FOXO3a (green) localization at ×20 magnification in control cells and cells treated with 0.1 and 0.5 μmol/L AZD8186 for 2 hours. A representative dose–response plot (of three experiments) of relative nuclear translocation for each line is shown [mean relative Foxo translocation (± SD)]. D, AZD8186 activity in a 72-hour MTS cell proliferation assay; relationship of most sensitive lines (classified as <1 μmol/L GI50) with PTEN genetic status (green, WT; red, MT; blue, increased copy number; gray, incomplete data). E and F, sensitivity of AZD8186 and AZD5363 (AKTi) in MTS cell proliferation assay and relationship to SGK-1 mRNA expression in a panel of breast cancer cell lines (E) and prostate cancer cell lines (F). SGK expression: blue, low; and red, high expression. GI50 data: red bars, resistant; green bars, sensitive to compound. Western blot analysis of PTEN protein expression for each cell line is shown; NT, not tested.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    In vivo activity of AZD8186. A, HCC70 tumors treated with vehicle (closed circles), 50 mg/kg (closed triangles), and 25 mg/kg (open inverted triangles) AZD8186 twice a day (b.i.d.). Modulation of the biomarkers pAKT Ser473 (B), pAKT Thr308 (C), and pPRAS40 (D) in HCC70 tumors by 50 and 25 mg/kg AZD8186 the times indicated. The mean percentage of inhibition (± SD) is shown. E, MDA-MB-468 tumors treated with vehicle (closed circles), 50 mg/kg (closed triangles), and 25 mg/kg (open inverted triangles) AZD8186 twice a day. Modulation of the biomarkers pAKT Ser473 (F), pAKT Thr308 (G), and pPRAS40 (H) in MDA-MB-468 tumors by 50 and 25 mg/kg AZD8186 at times indicated. The mean percentage of inhibition (±SD) is shown. I, PC3 tumors treated with vehicle (closed circles), AZD8186 at 25 mg/kg (open triangles), and 50 mg/kg (closed triangles) twice a day. J, HID28 tumors were treated with vehicle (closed circles) and AZD8186 at 50 mg/kg (closed triangles) twice a day. K, a representative PK profile of AZD8186 dosed twice a day with and without ABT (once in a 24 hours dosing cycle). L, PC3 tumors treated with vehicle + ABT (closed circles) and 30 mg/kg AZD8186 + ABT (open diamonds). M, HCC70 tumors treated with vehicle (closed circles), AZ8186 at 50 mg/kg twice a day (closed triangles), 50 mg/kg twice a day (4 days on, 3 days off; inverted closed triangles); or (N) treated with vehicle (closed circles), AZ8186 at 25 mg/kg twice a day (open inverted triangles), 25 mg/kg twice a day (5 days on, 2 days off; closed triangles). Geometric mean tumor volume ± SEM are shown. Statistical significance relative to control *, P < 0.05; ** P < 0.01; ***, P < 0.001.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    AZD8186 modulates pAKT and nuclear translocation of FOXO3a. Representative images of pAKT Ser473 and FOXO3a staining in HCC70, MDA-MB-468, PC3, and HID-28 tumors. Vehicle-treated and AZD8186-treated samples are shown. PC3 samples, vehicle control (8 hours after dose) and 30 mg/kg AZD8186 (30 minutes after dose). For HID28, vehicle and 50 mg/kg AZD8186 (2 hours after dose). For HCC70, vehicle and 50 mg/kg AZD8186 (30 minutes after dose). For MDA-MB-468, vehicle and 50 mg/kg AZD8186 (2 hours after dose). Images were taken at ×20 magnification. A, pAKT Ser473 staining. B, Foxo3a staining.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    AZD8186 combines with docetaxel. A, HCC70 tumors treated with control (closed circles), single dose 15 mg/kg docetaxel (closed star), and single dose (arrow) 15 mg/kg docetaxel with 50 mg/kg (closed triangles) or 25 mg/kg (inverted open triangles) twice a day (b.i.d.). Right-hand graph, single-agent AZD8186 50 mg/kg (closed triangles) and 25 mg/kg (inverted open triangles). B, PC3 tumors treated with control (closed circles), single dose (arrow) 15 mg/kg docetaxel (closed star) and single dose 15 mg/kg docetaxel with 30 mg/kg (closed diamonds) and 10 mg/kg (open diamonds) AZD8186 twice a day (plus ABT). The single-agent effect for 30 mg/kg (closed diamonds) and 10 mg/kg (open diamonds; plus ABT) AZD8186 is shown in the right hand graph. ##, P < 0.01; ###, P < 0.005. C, HCC70 tumors treated with vehicle (closed circles) and 25 mg/kg AZD8186 twice a day (inverted open triangles); D, with vehicle (closed circles), single dose (arrow) docetaxel (15 mg/kg; closed stars) alone or in combination with 25 mg/kg AZD8186 (twice a day; inverted closed triangles), or 25 mg/kg 2 days on 5 days off (inverted open triangles); E, with vehicle (closed circles), single dose (arrow) docetaxel (15 mg/kg; closed stars) alone or in combination with 25 mg/kg AZD8186 (twice a day; inverted closed triangles), or 25 mg/kg 5 days on 2 days off (inverted open triangles). Geometric mean tumor volume ± SEM are shown. Statistical significance: on combination studies * indicates comparison with the docetaxel alone control and # indicates comparison with the corresponding AZD8186 monotherapy control; *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.05; ##, P < 0.01; ###, P < 0.001.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Potency of AZD8186 in biochemical and cell based assays

    Biochemical assayIC50μmol/L ± SEM (n)Cell isoform selectivity: cell lineModulation of pAKT IC50μmol/L ± SEM
    PI3Kα0.035 ± 0.005PI3Kα: BT4740.752 ± 0.293
    PI3Kβ0.004 ± 0.001PI3Kβ: MDA-MB-4680.003 ± 0.001
    PI3Kδ0.012 ± 0.002PI3Kδ: JEKO0.017 ± 0.004
    PI3Kγ0.675 ± 0.114PI3KγNT

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Tables 1-3 and Figure 1-7 - Supplementary Tables 1-3 and Figure 1-7. Supp Table 1 Summary of cell line origins and verification. Supp Table 2 Summary of antibodies used in all experimental analysis Supp Fig 1 AZD8186 inhibits PI3K pathway in PTEN null but not PTEN WT PIKC3A MT cells Supp Fig 2 AZD8186 inhibits LPA, EGF and rac dependent Ser473 AKT phosphorylation in serum starved prostate and breast cancer cells Supp Fig 3 Western blot analysis of showing induction of FOXO3a association with the chromatin fraction following treatment with AZD8186 Supp Fig 4 AZD8186 inhibits proliferation in a subset of cancer cell lines Supp Table 3 GI50 of all cell lines showing sensitivity to AZD8186 Supp Fig 5 Western blot protein analysis of PTEN status across a panel of breast and prostate cell lines Supp Fig 6 Pathway biomarker suppression in PC3 and HID28 tumours Supp Fig 7 AZD8186 selectively suppresses pathway biomarkers in tumour versus lung
    • Supplementary Materials text - Supplementary Materials text. Supplementary text to support supplementary data.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (1)
January 2015
Volume 14, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafter, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D'Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green and Simon T. Barry
Mol Cancer Ther January 1 2015 (14) (1) 48-58; DOI: 10.1158/1535-7163.MCT-14-0406

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafter, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D'Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green and Simon T. Barry
Mol Cancer Ther January 1 2015 (14) (1) 48-58; DOI: 10.1158/1535-7163.MCT-14-0406
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sertraline Targets Serine/Glycine Synthesis Enzyme SHMT
  • Combination BETi/MEKi Treatments in Ovarian Cancer
  • Discovery of a Novel Anticancer Therapeutic
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement